Table 1. Baseline characteristics of all patients (n=33).
| Variable | Number (%) |
|---|---|
| Median age (range) | 52 (39–65) |
| Sex | |
| Male | 19 (58) |
| Female | 14 (42) |
| Disease stage (ISS) | |
| I | 5 (15) |
| II | 12 (36) |
| III | 13 (39) |
| Unknown | 3 (10) |
| Myelomas Subtype | |
| IgG | 12 (37) |
| IgA | 10 (30) |
| IgD | 1 (3) |
| IgM | 1 (3) |
| Light chain | 8 (24) |
| Non-secretory | 1 (3) |
| Cytogenetic risk stratification | |
| High risk | 10 (30) |
| Standard | 16 (48) |
| Unknown | 7 (22) |
| Donor type | |
| Sibling | 20 (61) |
| Unrelated | 13 (39) |
| Transplant timing | |
| Upfront | 18 (55) |
| Deferred | 15 (45) |
| Disease status post ASCT | |
| CR/sCR | 8 (24) |
| VGPR | 10 (30) |
| PR | 15 (43) |
| SD | 1 (3) |
| Median days between diagnosis and transplant (range) | |
| Upfront | 269 (149–3869) |
| Deferred | 1498 (261–5881) |
| Median days between ASCT and allo SCT (range) | 106 (50–693) |
Abbreviations: ASCT, autologous stem cell transplantation; ISS, International Staging System; PR, partial response; SCT, stem cell transplantation; SD, stable disease.
Standard risk cytogenetics=any result other than 17p-, t(4;14) or t(14;16).